PAPERS AND SHORT REPORTS
Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom C R RIZZA, ROSEMARY J D SPOONER Abstract A five year survey of the treatment of patients in the United Kingdom suffering from haemophilia and related disorders was carried out on behalf of the directors of haemophilia centres. The survey showed an increase in the number of patients receiving treatment from the centres, a substantial increase in the total amount of therapeutic materials used, and an increase in the average amount of factor VIII or factor IX used yearly per patient. Home treatment became established for severely affected patients and accounted for roughly half of the total amount of material used. Study of the acquisition of factor VIII or factor IX antibodies (inhibitors) in patients with haemophilia A or haemophilia B showed no increase in antibodies during the survey period, despite the increased use of factor VIII and factor IX concentrates. The occurrence of acute hepatitis in treated patients was also studied and no increased incidence was observed. A near normal median expectation of life in patients with severe haemophilia A was found.
in 1976 by the Department of Health and Social Security in a memorandum (HC(76)4) to regional health authorities and family practitioners. The number of centres gradually increased over the years, and by 1980 there were 10 centres acting as reference centres and nearly 100 other centres.
Each reference centre is responsible for the provision of an advisory clinical and laboratory service to individual haemophilia centres in a wide area (referred to as a "supraregion"). Some centres have staff, laboratory and clinical facilities, and funds specifically allocated for the haemophilia work, but most centres are run by the staff of haematology departments, medical departments, or blood transfusion centres as part of their routine service commitment. All haemophilia centres, irrespective
Introduction ORGANISATION OF TREATMENT
The care of haemophiliacs in the United Kingdom is organised through recognised haemophilia centres situated in National Health Service hospitals throughout the country. The concept of these centres was established in Britain in 1954 to provide specialist diagnostic, registration, and treatment services for haemophilic patients. The present system, which incorporates three types of centres-haemophilia reference centres, haemophilia centres, and associate haemophilia centres-was defined (n=lO) El <20 <40 <60 <80 <100 <120 <140 <160 <180 <200 " <280 No 1977, 1978, 1979, and 1980 ( A-1.9--l-ff.11-Vill -dp,,,p.6- types of material used to treat carriers of haemophilia A, the use of cryoprecipitate and NHS factor VIII fluctuated greatly from year to year but there was a steady increase in the use of commercial factor VIII. In addition to the patients treated with blood products, four mildly affected carriers of haemophilia A were treated with desmopressin only. The total amount of factor VIII used in any one year for the treatment of carriers of haemophilia A accounted for less than 1% of the total factor VIII used in Britain. Throughout the period of the survey cryoprecipitate was the therapeutic material most used for the treatment of von Willebrand's disease, accounting for 75-90% of the factor VIII given to those patients. Besides preparations containing factor VIII other materials were infrequently used: in 1977 a patient with von Willebrand's disease and antibodies against factor VIII was treated with an activated prothrombin complex concentrate (FEIBA; "factor eight inhibitor bypassing activity") and porcine factor VIII, and in 1977 VIII, and in , 1978 VIII, and in , 1979 VIII, and in , and 1980 given to two, four, nine, and nine patients, respectively. The total amount of factor VIII used in any one year to treat carriers of haemophilia A and patients with von Willebrand's disease accounted for only 3-4%, of the total factor VIII used in Britain.
Very few carriers of haemophilia B required treatment during the survey period, the numbers fluctuating between five and 12 a year. Those patients were mainly treated with NHS factor IX concentrates, though fresh frozen plasma was occasionally used. The total amount of factor IX used in any one year ranged from 7000 to 115 000 units and accounted for 0-1-1-4% of the total amount of factor IX used in Britain in that year. such as the administration of larger doses for the management of haemarthroses or the widespread use of prophylactic treatment the total amount of factor VIII used will be still greater. During 1980 commercial factor VIII constituted 60% of the total factor VIII used and cost the NHS some £2-5 million. If the proportion of commercial factor VIII used in 1990 remains the same as today the cost at today's prices will be of the order of £5 million. But if, as seems likely from recent trends, there is an increase in the proportion of commercial factor VIII used the cost will be even higher. It is unlikely that the upward trend in the use of commercial factor VIII will be reversed before the middle to late 1980s, when the NHS fractionation laboratories are expected to increase greatly their output of factor VIII.
HEPATITIS
As in other reports intracranial bleeding is the commonest cause of death in patients suffering from haemophilia A. -nnphila .4 in B,i,.an (1976-80) and for iom mae En I.glad an,d Walh, (1977-9) f"'VlH,,,ophil,, The follovig d,-,t-of h-.phili. .nr mbti,d dt. to the haemophilia since factor VIII has become widely available and bleeding to death from trivial injury-so common in the pastis now rarely seen. We should therefore not be surprised at some increase in life expectation, but whether the improvement observed in this survey is an overestimate will remain to be seen. The directors of haemophilia centres in Britain are continuing with their collaborative studies, and it is hoped that further information collected over the next few years will answer this question.
In view of the widespread concern about the transmission of hepatitis viruses by giving blood products it is interesting to note that only two deaths were attributed to hepatitis during the five year period. There have been several reports recently of persistently abnormal liver function values and abnormal histological findings in liver tissue from haemophiliacs treated with blood products. Most of these patients are asymptomatic but it remains to be seen how many will develop severe chronic liver disease with the passage of time. 
